Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M VenturiniR Rosso

Abstract

Dexrazoxane was found effective in reducing doxorubicin cardiotoxicity when given at a dose ratio (dexrazoxane: doxorubicin) of 20:1. Preclinical studies indicated that dexrazoxane at a dose ratio of 10 to 15:1 also protected against epirubicin-induced cardiotoxicity. The main objective of this study was to investigate the efficacy of dexrazoxane, given at a dose ratio of 10:1 against epirubicin cardiotoxicity. One hundred sixty-two advanced breast cancer patients were randomized to receive epirubicin-based chemotherapy with or without dexrazoxane. Patients who had previously received adjuvant chemotherapy that contained anthracyclines were treated with cyclophosphamide 600 mg/m2 intravenously (IV), epirubicin 60 mg/m2 IV, and fluorouracil 600 mg/m2 IV, on day 1 every 3 weeks. The other patients were treated with epirubicin 120 mg/m2 IV on day 1 every 3 weeks. Cardiac toxicity was defined as clinical signs of congestive heart failure, a decrease in resting left ventricular ejection fraction (LVEF) to < or = 45%, or a decrease from baseline resting LVEF of > or = 20 EF units. One hundred sixty patients were evaluated. Cardiotoxicity was recorded in 18 of 78 patients (23.1%) in the control arm and in six of 82 (7.3%) in the dexra...Continue Reading

Citations

Mar 20, 1999·The Annals of Pharmacotherapy·I S Lossos, D Ben-Yehuda
May 2, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·V B Pai, M C Nahata
Jun 21, 2002·Clinical Pharmacokinetics·Romano DanesiMario Del Tacca
Dec 15, 2005·British Journal of Haematology·Karlijn A WoutersSteven E Lipshultz
Dec 23, 2008·Breast Cancer Research and Treatment·Joseph Gligorov, Jean-Pierre Lotz
Aug 20, 2009·Cardiology in Review·Kuldeep Maradia, Maya Guglin
Sep 19, 2014·Current Opinion in Oncology·Manali BhaveSteven T Rosen
May 20, 2016·British Journal of Clinical Pharmacology·Folefac AminkengUNKNOWN CPNDS Clinical Practice Recommendations Group
Dec 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saro H ArmenianDaniel Lenihan
Jun 26, 2018·Current Heart Failure Reports·Zarina Sharalaya, Patrick Collier
Oct 23, 2018·F1000Research·J Emanuel Finet, W H Wilson Tang
May 19, 2000·Breast Cancer Research and Treatment·A MichelottiP Conte
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Robin L Jones
Jun 17, 2011·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien Cm Kremer
Aug 21, 2013·Cancer Chemotherapy and Pharmacology·Duncan T VincentYuichiro J Suzuki
May 27, 2011·Leukemia & Lymphoma·Paul M Barr, Jonathan W Friedberg
Aug 4, 2015·Future Cardiology·Susan Piper, Theresa McDonagh
Dec 30, 2014·Frontiers in Oncology·Shuang Guo, Serena Wong
Aug 4, 2015·Future Cardiology·Nieves Montoro, Jose Luis López-Sendón
Nov 11, 2015·Circulation·Ronald M Witteles, Xavier Bosch
Oct 16, 1999·British Journal of Haematology·G Levitt
Nov 28, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Claudia LangebrakeJörg Ritter
Oct 30, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Ei IkegamiShunichi Ogawa
Sep 14, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Merry L LindseyGregory J Aune
Mar 3, 2012·Current Heart Failure Reports·Amir Y Shaikh, Jeffrey A Shih
Jan 5, 2014·Journal of Clinical Pharmacy and Therapeutics·S LimatE Deconinck
Jun 7, 2018·NPJ Precision Oncology·Xinqiang HanWendi Liu
Sep 20, 2012·Circulation. Cardiovascular Imaging·Steven E LipshultzJames D Wilkinson
Mar 29, 2020·Journal of Clinical Medicine·Robin KikuchiSusan F Dent
Aug 12, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Franco TestoreGiuseppina Bosso
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L HensleyD G Pfister
Oct 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Khojasteh GhasemiMarjan Mansourian

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.